S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%

Health and Healthcare

Drug Maker Prices Secondary Offering (GALE)

Photo of Paul Ausick
By Paul Ausick Published

Invalid Image
Biotech firm Galena Biopharma Inc. (NASDAQ: GALE) this morning priced a secondary offering of 8.5 million shares at $1.50/share, a discount of nearly 20% to last night’s closing price of $1.87. The company is offering an underwriter over-allotment option of 1.275 million shares, and expects to raise net proceeds of $11.6 million, excluding the underwriter’s option.

Galena develops cancer drugs and plans to use the net proceeds from this offering for:

working capital and other general corporate purposes, including the Phase 3 NeuVax(TM) (E75) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial, Phase 1/2 clinical trials of Foliate Binding Protein-E39 (FBP) and a planned Phase 2 trial of NeuVax in combination with Herceptin(R) (trastuzumab; Genentech/Roche).

Shares are down -14% at $1.61 in a 52-week range of $0.36-$3.54.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income
Michael Williams |

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income
The Real Cost of Retiring in The Villages, Florida, on $2,000 a Month
Michael Williams |

The Real Cost of Retiring in The Villages, Florida, on $2,000 a Month

Continue Reading

Jon C. Ogg |

Blockbuster Opportunity for Galena Biopharma? GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is unknown to most investors out there.  The company recently had news about the initiation…

Is Galena Dead in the Water After This Failed Trial?
Chris Lange |

Is Galena Dead in the Water After This Failed Trial?

Galena Biopharma, Inc. (NASDAQ: GALE) is absolutely crashing on Wednesday after the company released further information regarding its Breast Cancer…

7 Key FDA Decisions and Clinical Trial Results Coming in Q4
Chris Lange |

7 Key FDA Decisions and Clinical Trial Results Coming in Q4

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…

Forty Seven Announces Potential Pricing for IPO
Chris Lange |

Forty Seven Announces Potential Pricing for IPO

Clinical-stage immuno-oncology company Forty Seven intends to price more than 6 million shares so that the entire offering is valued…

Syndax Updates IPO FIling
Chris Lange |

Syndax Updates IPO FIling

Syndax Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange |

NantKwest Sets Price Range for IPO

NantKwest has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Mersana Therapeutics Closes in on IPO After Announcing Expected Price Range
Chris Lange |

Mersana Therapeutics Closes in on IPO After Announcing Expected Price Range

Mersana Therapeutics expects to price its 5 million shares in the range of $14 to $16 apiece in an initial…

8 Major Biopharma Events Coming Later in 2016 and in 2017
Chris Lange |

8 Major Biopharma Events Coming Later in 2016 and in 2017

FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in…

Chris Lange |

How the Inovio Secondary Crushed Its Shareholders

A lot of times when companies have secondary offerings the price takes a slight dip to accommodate the dilution and…

Top Gaining Stocks

Airbnb
ABNB • Vol: 15,913,532
Microchip Technology
MCHP • Vol: 19,139,274
Palantir
PLTR • Vol: 77,244,625
Moderna
MRNA • Vol: 6,820,582
Axon Enterprise
AXON • Vol: 1,591,869

Top Losing Stocks

Trade Desk
TTD • Vol: 133,458,224
Coterra Energy
CTRA • Vol: 73,319,495
Akamai
AKAM • Vol: 8,143,961
Zoetis
ZTS • Vol: 12,784,553
ResMed
RMD • Vol: 3,810,438